Related Experiment Video
Updated: Sep 12, 2025
Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
Published on: May 24, 2024
Branched-Chain Amino Acid Supplementation and Clinical Outcomes in Liver Cirrhosis: A Propensity Score-Matched
Mohammad Aldiabat1,2, Yazan Aljabiri2, Wesam Aleyadeh3
1Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA.
Purpose:
Branched-Chain Amino Acid (BCAA) supplementation has shown benefits in reducing liver cirrhosis complications, improving survival, and potentially lowering hepatocellular carcinoma risk, but evidence on long-term outcomes remains limited. This real-world study evaluates clinical outcomes of liver cirrhosis patients receiving BCAA supplementation.
Methods:
This retrospective cohort study used the TriNetX US Collaborative Network to identify liver cirrhosis patients aged ≥ 18 years, stratified by BCAA supplementation after diagnosis. Propensity score matching (PSM) balanced cohorts by demographics, body mass index, Model for End-Stage Liver Disease (MELD) score components, and baseline history of cirrhosis complications, including hepatic encephalopathy (HE), sarcopenia, spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), and falls. Composite and individual outcomes within 5 years were assessed using odds ratios (OR) with 95% confidence intervals (CI).
Results:
Among 2,176 matched patients per group, BCAA supplementation was associated with lower rates of the composite outcome (OR 0.81, 95% CI: 0.71-0.92), HE (OR 0.63, 95% CI: 0.49-0.79), SBP (OR 0.77, 95% CI: 0.60-0.99), falls (OR 0.64, 95% CI: 0.53-0.78), all-cause emergency room visits (OR 0.56, 95% CI: 0.50-0.64), and hospitalizations (OR 0.68, 95% CI: 0.60-0.76). Liver transplantation occurred more frequently in the BCAA group (OR 1.49, 95% CI: 1.08-2.06). Sarcopenia rates were similar (OR 1.00, 95% CI: 0.42-2.41), while AKI was slightly more frequent (OR 1.13, 95% CI: 1.00-1.28). Subgroup analysis showed greater benefit in viral hepatitis-associated (OR 0.69, 95% CI: 0.53-0.90) and alcohol-associated cirrhosis (OR 0.73, 95% CI: 0.60-0.89), compared to MASLD (OR 0.81, 95% CI: 0.60-1.08).
Conclusion:
BCAA supplementation was associated with significant reductions in several cirrhosis-related complications, with most benefits observed in viral hepatitis-associated and alcohol-associated cirrhosis.
More Related Videos
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
01:24Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
01:09Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...